Stay informed with the Divis Labs Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of ...

Vinay Rajani of HDFC Securities says Divis Labs share price has broken out from the box pattern on the daily chart with the ...

Welcome to the Divis Labs Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

Amid the rising volatility in the Indian equity markets, domestic brokerage firm BP Equities has shared its top picks for ...

Multiple experts are converging on select pharma, FMCG, media, and financial services counters. Key names on today’s radar ...

Stock market today: Indian equity indices remained largely unchanged on Wednesday as financial stocks retraced from their near-record peaks, counterbalancing the positive sentiment surrounding a ...

Citi said it believes Divi's Laboratories' revenue and earnings before interest, tax, depreciation, and amortisation (EBITDA) ...

Revenue stood at INR 25,850 Mn., up 12.2% YoY, below our estimates by 9.1%, led by weaker growth in Custom Synthesis segment. EBITDA came in at INR 8,860 Mn., up by 21.2% YoY (+19.2% QoQ), largely ...

Earnings call Divi's Laboratories posted a 25.4% YoY revenue growth for Q3 FY25, with PAT rising 64.5% YoY. Custom synthesis continues to drive growth, while backward integration via the new Kakinada ...

Shares of Divis Laboratories rose 3 percent to Rs 6,188 on Friday, August 22, after global brokerage Citi turned upbeat on the stock, flagging attractive valuations and sector tailwinds. Citi ...

Divi's Laboratories proposes ₹30 per share final dividend for FY25 Stock price reaches record ₹6,764, up 4.37 percent New long-term pharma supply deal triggers ₹650-750 crore investment Shares of ...

Earnings call Divi’s Laboratories reported Q2 FY25 consolidated revenue of ₹2,444 crore, up 22.5% YoY and 11.2% QoQ. Profit after tax rose to ₹510 crore, up 46.6% YoY. Custom synthesis now contributes ...